DoSurvive: A webtool for investigating the prognostic power of a single or combined cancer biomarker

Hao-Wei Wu; Jian-De Wu; Yen-Ping Yeh; Timothy H Wu; Chi-Hong Chao; Weijing Wang; Ting-Wen Chen

doi:10.1016/j.isci.2023.107269

DoSurvive: A webtool for investigating the prognostic power of a single or combined cancer biomarker

iScience. 2023 Jul 4;26(8):107269. doi: 10.1016/j.isci.2023.107269. eCollection 2023 Aug 18.

Authors

Hao-Wei Wu¹, Jian-De Wu¹, Yen-Ping Yeh¹, Timothy H Wu², Chi-Hong Chao^{3

4

5}, Weijing Wang⁶, Ting-Wen Chen^{1

4

5}

Affiliations

¹ Institute of Bioinformatics and Systems Biology, National Yang Ming Chiao Tung University, Hsinchu 30068, Taiwan.
² Institute of Ecology and Evolutionary Biology, National Taiwan University, Taipei 10617, Taiwan.
³ Institute of Molecular Medicine and Bioengineering, National Yang Ming Chiao Tung University, Hsinchu 30068, Taiwan.
⁴ Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu 30068, Taiwan.
⁵ Center For Intelligent Drug Systems and Smart Bio-devices (IDSB), National Yang Ming Chiao Tung University, Hsinchu 30068, Taiwan.
⁶ Institute of Statistics, National Yang Ming Chiao Tung University, Hsinchu 30068, Taiwan.

Abstract

We present DoSurvive, a user-friendly survival analysis web tool and a cancer prognostic biomarker centered database. DoSurvive is the first database that allows users to perform multivariant survival analysis for cancers with customized gene/patient list. DoSurvive offers three survival analysis methods, Log rank test, Cox regression and accelerated failure time model (AFT), for users to analyze five types of quantitative features (mRNA, miRNA, lncRNA, protein and methylation of CpG islands) with four survival types, i.e. overall survival, disease-specific survival, disease-free interval, and progression-free interval, in 33 cancer types. Notably, the implemented AFT model provides an alternative method for genes/features which failed the proportional hazard assumption in Cox regression. With the unprecedented number of survival models implemented and high flexibility in analysis, DoSurvive is a unique platform for the identification of clinically relevant targets for cancer researcher and practitioners. DoSurvive is freely available at http://dosurvive.lab.nycu.edu.tw/.

Keywords: Cancer systems biology; Epigenetics; Proteomics; Transcriptomics.